Search Results

Rocket Pharmaceuticals, Inc. announced longer-term data updates from its lentiviral vector hematology portfolio presented at the 27th Annual Meeting of the American Society of Gene and Cell Therapy.

The American Cancer Society and the American Society of Clinical Oncology announced an expanded collaboration to make it simpler for patients to find authoritative cancer information online.

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3DOA), (the “Company” or “Telo”), an emerging molecular testing platform provider leveraging the power of telomeres, looks forward to attending the American Society of Hematology (ASH) annual meeting in San Diego this week.

Takeda to Present Data at 65th American Society of Hematology (ASH) Annual Meeting, Demonstrating Continued Commitment to Patients with Hematologic Diseases.

Singleron Biotechnologies has announced two co-authored abstracts for the upcoming 65th American Society of Hematology Annual Meeting & Exposition in San Diego.

Telo Genomics Corp. is thrilled to announce that the manuscript titled, “Three-dimensional telomere profiling predicts risk of progression in smoldering multiple myeloma” was accepted for publication in the American Journal of Hematology.

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the upcoming presentation of four posters highlighting data from their commercial and clinical-stage hematology-oncology portfolio at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 9-12, 2023, in San Diego, California and virtually.

Keros Therapeutics, Inc. announced that five abstracts will be presented from its hematology program at the 65th American Society of Hematology Annual Meeting and Exposition to be held in person and virtually from December 9 through 12, 2023.

Pfizer Inc. will present its latest data showcasing advances in the treatment of hemophilia, sickle cell disease, and blood cancers at the 65th American Society of Hematology Annual Meeting and Exposition in San Diego from December 9-12.

Invivyd, Inc. announced that it will present preliminary, subset analyses from the CANOPY Phase 3 clinical trial of VYD222 for pre-exposure prophylaxis of COVID-19 at the 2024 American Society of Clinical Oncology Annual Meeting and at the 2024 American Transplant Congress.